[ad_1]
Jakarta, CNBC Indonesia – Sinovac Biotech finally raised its voice on Brazil’s policy of temporarily suspending clinical trials of the Covid-19 CoronaVac vaccine. This clinical trial was stopped as of October 29, 2020.
“We have paid attention to various media reports. After communicating with our partners from the Brazilian Institute Butantan, we know that the head of the Butantan Institute believes that this serious adverse event (SAE) is not related to vaccines,” Sinovac said in his official statement, quoted on Wednesday (11). / 11/2020)
“Sinovac will continue to communicate with Brazil on this issue. The clinical study in Brazil was carried out strictly in accordance with the requirements of GCP and we are confident in the safety of the vaccine.”
On Tuesday (11/10/2020), the Brazilian health authority Anvisa announced the suspension of the clinical trial of the Covid-19 CoronaVac vaccine. The reason was that there were incidents that were costly without a more detailed explanation.
The director of the Butantan Sao Paulo Institute, Dimas Covas, suspected that the postponement was due to one of the volunteers who died but “the death was not related to the vaccine” so he was surprised by the decision of the Brazilian Health Agency Anvisa .
“There are more than 10,000 volunteers [vaksin] at this time, deaths can occur … They are deaths that have nothing to do with vaccines and therefore it is not the time to stop the trials, “said Dimas Covas, as quoted by Reuters.
FYI, Sinovac began its end-stage clinical trials in June 2020 in several countries, including China, Brazil, Indonesia, and Turkey. So far, there have been no reports of harmful side effects from clinical trials of the Sinovac vaccine in China, Turkey, and Indonesia.
[Gambas:Video CNBC](roy / sef)
